EGRX | Ticker Profile - Titan Protect

EGRX

Eagle Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic · PNK

$0.60

Data: 2026-05-13

✗ ETHICAL FAIL

WEAK MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$3M

Total market value of the company

Trailing P/E

2.50

Very cheap relative to earnings

Forward P/E

0.07

Based on estimated future earnings — lower means cheaper

Rev Growth

-12.8%

Year-over-year revenue change

Profit Margin

4.6%

How much profit the company keeps from each dollar of revenue

ROE

4.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

NONE

Consensus view from ? analysts covering this stock

About Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

https://www.eagleus.com

Country: United States Employees: 134 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

2,202.7% FAIL

Debt must be below 33% of total assets

Cash Ratio

466.8% FAIL

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.

$52.20

What our model estimates this business is worth per share

Margin of Safety

98.9%

Deep discount to fair value — significant undervaluation

Rating

AVOID

Overall assessment combining ethics, valuation, and quality

Percentile

37.9th

Ranks in the top 62% of our 13,571 screened universe

Ethical Score

10.0

Valuation Score

95.0

Quality Score

28.3

Combined

N/A

Trading at $0 against a fair value of $52, a 100% discount. Fails ethical screen (Debt ratio). Ranks better than 72% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

1.374

Excellent risk-adjusted returns

Kelly Fraction

0.0219

Modest edge detected — smaller position warranted

Calmar Ratio

-0.620

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-62.0%

Historical annualised return based on price data

Max Drawdown

-100.0%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.60

Less volatile than the market — more defensive

52W High

$3.87

84% below the year high

52W Low

$0.00

59900% above the year low

Avg Volume

272

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

4.2%

Low short interest — limited bearish positioning

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$0.10

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.29

Conservative use of debt — low financial risk

Current Ratio

2.16

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

1.51

Like current ratio but excludes inventory — stricter test

Gross Margin

69.8%

Revenue left after cost of goods — higher means pricing power

Operating Margin

15.9%

Profit from core operations before interest and tax

Free Cash Flow

$38M

Positive — the business generates more cash than it spends

Revenue (TTM)

$258M

Total revenue over the last 12 months

Net Income

$12M

Profitable — the bottom line is positive

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-13

Before you go